Aztreonam–avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance
Authors:
- 26 May 2026
- journal article
- review article
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 79 (7) , 425-436
Abstract
Metallo-β-lactamase (MBL)–producing Gram-negative bacteria pose a significant problem to antibiotic treatment due to their ability to inactivate most β-lactam antibiotics and resist inhibition by conventional β-lactamase inhibitors. While aztreonam–avibactam (ATM–AVI) has proven to be an effective treatment for these bacteria, previous reviews have been largely narrative, either from a microbiological perspective or a clinical perspective in isolation. This review seeks to provide a mechanism-based and translational synthesis of ATM–AVI by combining molecular antibiotic science, pharmacokinetic/pharmacodynamic (PK/PD) concepts, antimicrobial susceptibility testing, and clinical data. The mechanism of action of ATM–AVI is based on the natural stability of aztreonam to MBLs, resistance to co-produced serine β-lactamases by avibactam, and appropriate exposure strategies to ensure target attainment. There is consistent activity against MBL-producing Enterobacterales and Pseudomonas aeruginosa in surveillance and clinical trials, but emerging resistance due to PBP3 insertions, porin mutations, and efflux pump overexpression identifies important biological targets. The future clinical utility of ATM–AVI will depend on mechanism-based susceptibility testing, rapid diagnostic integration, and stewardship-driven use, particularly in high-prevalence settings. Beyond its current clinical utility, ATM–AVI provides insight into principles for the rational development and responsible use of next-generation antibiotics in the face of complex resistance.Keywords
This publication has 68 references indexed in Scilit:
- Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value FrameworkInfectious Diseases and Therapy, 2025
- Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream InfectionsJAMA Network Open, 2024
- Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coliEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluationEuropean Journal of Clinical Pharmacology, 2024
- International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021European Journal of Clinical Microbiology & Infectious Diseases, 2023
- Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative BacteriaClinical Drug Investigation, 2023
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- The β‐Lactams Strike Back: Ceftazidime‐AvibactamPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015